The Levine Cancer Institute of the Carolinas HealthCare System has had a large impact on hematopoietic cell transplant outcomes.
Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program
Managed care organizations can contribute to improved outcomes and reduced costs by increasing the understanding of current therapies, recognizing the potential benefit of future therapies, and developing an understanding of targeted drugs and their place in therapy.
A Novel Clinical Pathways Approach to Delivering Regional-Based Clinical Trials and Patient Care in a Hybrid Academic-Community-Based System
Since 2015, the Levine Cancer Institute, Atrium Health, has created and utilized the Electronically Accessible Pathways, which has helped drive standardization and enhance provider and patient diagnostic and treatment knowledge across its regional network.
Through implementing processes set forth by OCM practice requirements and analyzing beneficiary claims data made available through participation in the program, Clearview Cancer Institute has successfully identified eligible patients, completed required documentation points, and increased awareness and outcomes for patients related to depression screening, hospitalizations, emergency room use, and hospice use.
As most cancer patients are seen in the community setting, community oncologists will play an instrumental role in patient referral and likely determine the initial adoption of CAR-T therapies.
Creating Value in Cancer Care Through Standardized Metrics and Partnerships Between Patient Navigators and Physicians
While providers and care systems can agree that effective patient navigation programs are essential to positive patient outcomes, there have been no standard metrics that could be used to measure the success of navigation programs and establish benchmarks for improvement.
The promise of CAR-T therapies as a potential cure for cancers and the pressure that this creates in the market will likely serve to highlight the ineffective areas in our health care system, as providers contend with multiple barriers associated with the therapy.
Researchers identified critical educational gaps that need to be addressed by manufacturers and policymakers in order for biosimilars to achieve their potential for lowering the cost of cancer care in the United States.
The simulation provided an opportunity for meeting attendees to observe the process by which oncologists determine initial diagnostic tests critical to treatment selection, the most appropriate treatment for each line of therapy, and criteria for subsequent treatment selection.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.